Following its announcement on 17 January 2017, Onzima Ventures Plc (“Onzima” or the “Company”), is pleased to announce the conditional acquisition of the remaining 51 per cent. of the issued shares of N4 Pharma Limited (“N4 Pharma”) which it does not already own (the “Acquisition”). Consideration for the Acquisition will be satisfied by the issue of 4,510,800 New Ordinary Shares and 4,591,400 Deferred Consideration Shares (post-Share Re-Organisation).
Amryt Pharma was established as a platform to acquire, build, develop and commercialise a range of drugs targeted at niche, orphan diseases, thereby creating a Specialty Pharmaceutical business. The company has acquired two companies which have brought in two products, one with European regulatory approval, which it is looking to expand into more indications. The company is led by a strong management team with considerable pharmaceutical experience. Amryt has a market capitalisation of £50m which compares very favourably with peers developing similar orphan assets, suggesting there is solid upside potential.
LSE Share Talk interviews Satu Vainikka – CEO of Valirx PLC